Synthesis and Evaluation of Mutual Azo Prodrugs of Sulfamethoxazole and Salicylic Acid Derivatives for Colon Targeted Release
Pharmaceutical Science-Public Health
DOI:
https://doi.org/10.22376/ijlpr.2023.13.1.P56-72Keywords:
IBDs, Ulcerative Colitis, Mutual Azo Prodrug Approach, Enzyme Degradation, and Colon Targeted Drug Delivery.Abstract
Several adverse effects are related to medications that treat moderate to severe inflammatory bowel diseases (IBDs). Targeted drug administration is necessary to treat inflammatory bowel disease to maximize efficacy and minimize toxicity. This study investigated the prodrug approach for antibacterials that target the colon. We chose sulfonamide (Sulfamethoxazole) as an antibiotic to target the colon. The prodrug approach is one of the most effective treatments for inflammatory bowel disease (IBD), and this mutual azo prodrug might serve the same function. This investigation aims to synthesize mutual azo prodrugs (S1-S5) and evaluate the colon-targeted release (in-vitro and in-vivo release studies). The objective of synthesizing mutual azo prodrugs (S1- S5) is that due to the high molecular weight of synthesized prodrugs (>500), they will enter the colon intact and not be absorbed in the upper GIT (Lipinski rule of 5). A coupling reaction between the sulfamethoxazole diazonium salt and salicylic acid derivatives allowed for synthesizing of mutual azo prodrugs (S1-S5). By monitoring the chemical reactions, the purity of the synthesized prodrugs was assessed, and by using FTIR, NMR (1H and 13C), Mass Spectrometry (MS), and Elemental Analysis, the structures of newly synthesized mutual azo prodrugs (S1-S5) were analyzed. Studies on the in-vitro stability of synthesized prodrugs showed less release after 6 hours in HCl buffer (pH 1.2), and only 10% release after 6 hours in phosphate buffer (pH 7.4) was observed. The sensitivity of the synthesized azo prodrug to the bacterial enzyme azoreductase was shown by incubating the azo prodrugs with the cecal contents of a rat; the release results showed that the release of free drugs from the azo prodrugs was more than 80%. Using trinitrobenzene sulfonic acid (TNBS)-induced colitis rats model, the in-vivo study was evaluated, and results revealed that mutually synthesized azo prodrugs are effective as 5-aminosalicylic acid in ulcerative colitis. Based on the release studies results, it is concluded that the azo prodrugs are a potential therapeutic target for ulcerative colitis.
References
Leeson P. Drug Discovery: chemical beauty contest. Nature.2012;481(7382):455-6. doi: 10.1038/481455a, PMID 22281594.
Rautio J, Meanwell NA, Di L, Hageman MJ. The expanding role of prodrugs in contemporary drug design and development. NatRev Drug Discov. 2018Aug;17(8):559-87. doi: 10.1038/nrd.2018.46, PMID 29700501.
Hacker M, Messer W, Bachmann K. Chapter 10.5.Elimination (metabolism and excretion). Londan: Elsvier Academic Press. In: Pharmacology: principles and practice; 2009. p.216.
Renukuntla J, Vadlapudi AD, Patel A, Boddu SH, Mitra AK. Approaches for enhancing oral bioavailability of peptides and proteins. Int J Pharm.2013Apr15;447(1-2):75-93. doi: 10.1016/j.ijpharm.2013.02.030, PMID 23428883.
Raghavan CV, Muthulingam C, Jenita JA, Ravi TK. An in vitro and in vivo investigation into the suitability of bacterially triggered delivery system for colon targeting. Chem Pharm Bull (Tokyo).2002Jul;50(7):892-5. DOI: 10.1248/CPB.50.892, PMID 12130845.
Kumar P, Mishra B. Colon targeted drug delivery systems-an overview. Curr DrugDeliv.2008Jul;5(3):186-98. doi: 10.2174/156720108784911712, PMID 18673262.
Chourasia MK, Jain SK. Pharmaceutical approaches to colon targeted drug delivery systems. J Pharm Pharm Sci.2003Jan-Apr;6(1):33-66. PMID 12753729.
Sinha VR, Kumria R. Polysaccharides in colon-specific drug delivery. Int J Pharm.2001Aug14;224(1-2):19-38. doi: 10.1016/s0378-5173(01)00720-7, PMID 11472812.
Singh UP, Singh NP, Busbee B, Guan H, Singh B, Price RL, Taub DD, Mishra MK, Nagarkatti M, Nagarkatti PS. Alternative medicines as emerging therapies for inflammatory bowel diseases. Int Rev Immunol. 2012 Feb;31(1):66-84. doi: 10.3109/08830185.2011.642909,, PMID: 22251008.
Jain A, Gupta Y, Jain SK. Azo chemistry and its potential for colonic delivery. Crit Rev Ther Drug Carrier Syst.2006;23(5):349-400. doi: 10.1615/critrevtherdrugcarriersyst.v23.i5.10, PMID 17425512.
Jain A, Gupta Y, Jain SK. Perspectives of biodegradable natural polysaccharides for site-specific drug delivery to the colon. J Pharm Pharm Sci.2007;10(1):86-128. PMID 17498397.
Jain A, Gupta Y, Jain SK. Potential of calcium pectinate beads for target specific drug release to colon. J Drug Target.2007May;15(4):285-94. doi: 10.1080/10611860601146134, PMID 17487697.
Karrout Y, Neut C, Wils D, Siepmann F, Deremaux L, Flament MPet al.Novel polymeric film coatings for colon targeting: drug release from coated pellets. Eur J Pharm Sci.2009Jun28;37(3-4):427-33. DOI: 10.1016/j.ejps.2009.03.014, PMID 19491034.
Smith HW. The development of the flora of the alimentary tract in young animals. J Pathol Bacteriol.1965Oct;90(2):495-513. DOI: 10.1002/path.1700900218, PMID 4285022.
Rubinstein A. Natural polysaccharides as targeting tools of drugs to the human colon. Drug DevRes. 2000Jul;50(3-4):435-9. doi:10.1002/1098-2299(200007/08)50:3/4<435::AID-DDR26>3.0.CO;2-5.
Schellekens RCA, Stuurman FE, Van der Weert FH, Kosterink JG, Frijlink HW. A novel dissolution method relevant to intestinal release behaviour and its application in the evaluation of modified release mesalazine products. Eur J Pharm Sci.2007Jan;30(1):15-20. DOI: 10.1016/j.ejps.2006.09.004, PMID 17085024.
Chan RP, Pope DJ, Gilbert AP, Sacra PJ, Baron JH, Lennard-Jones JE. Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide. Dig Dis Sci. 1983Jul;28(7):609-15. doi: 10.1007/BF01299921, PMID 6345112.
Dew MJ, Hughes PJ, Lee MG, Evans BK, Rhodes J. An oral preparation to release drugs in the human colon. Br J Clin Pharmacol. 1982Sep;14(3):405-8.doi: 10.1111/j.1365-2125.1982.tb01999.x, PMID 7126413.
Peppercorn MA, Goldman P. The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J Pharmacol Exp Ther.1972Jun;181(3):555-62. PMID 4402374.
Available from: http://www.newworldencyclopedia.org/entry/Azo_compounds[cited2/11/2022].
Remington JP. Remington: the science and practice of pharmacy. 21st ed.Philadelphia:Lippincott Williams & Wilkins; 2006. p. 1630-3.
Nazeruddin GM, Suryawanshi SB. Synthesis of Novel Mutual Pro-drugs by coupling of ibuprofen (NSAID) with sulfa drugs. JChemPharmRes.2010;2(4):508-12.
ShaymaLuayAbdulhadi QJ. Ahlam. Synthesis of NSAID with sulfonamide conjugates as possible mutual prodrugs using amino acid spacer. IJAPBC. 2013Jan-Mar;2(1):241-8.
Mustafa. Synthesis and kinetic studies of mutual azo prodrugs of 5-aminosalicylic acid with Sulfamethoxazole and trimethoprim as models for colon targeting, Iraq.J Pharmacol. 2010;9(1):21-31.
ShivajiKM, PrashantPA, ChetanPB, AnilPS. Synthesis and characterization of prodrugs of sulfonamides as an azo derivatives of carvacrol. Pharm Chem.2018;10(12):1-15.
PetriWAJr. Therapy of intestinal protozoa. Trends Parasitol.2003Nov;19(11):523-6. DOI: 10.1016/j.pt.2003.09.003, PMID 14580964.
StanleySLJr. Amoebiasis. Lancet. 2003Mar22;361(9362):1025-34. doi: 10.1016/S0140-6736(03)12830-9, PMID 12660071.
Freeman CD, Klutman NE, Lamp KC. Metronidazole. A therapeutic review and update. Drugs. 1997Nov;54(5):679-708. doi: 10.2165/00003495-199754050-00003, PMID 9360057.
Goodman LS, Gilman A, Brunton LL, Lazo JS, Parker KL. Goodman&Gilman’s the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill; 2006. p. 1050.
Ludlum DB, Colinas RJ, Kirk MC, Mehta JR. Reaction of reduced metronidazole with guanosine to form an unstable adduct. Carcinogenesis. 1988Apr;9(4):593-6. DOI: 10.1093/carcin/9.4.593, PMID 3356067.
Leitsch D, Kolarich D, Wilson IB, Altmann F, Duchêne M. Nitroimidazole action in Entamoeba histolytica: a central role for thioredoxin reductase. PLOSBiol.2007Aug;5(8):e211. DOI: 10.1371/journal.pbio.0050211, PMID 17676992.
Furniss BS, Hannaford AJ, Smith PWG, Tatchell AR. Vogel’stextbook of practicalorganicchemistry. 5th ed. London: Longman Scientific & Technical; 1989. p. 920.
Fakri Mustafa Y. Synthesis and kinetic studies of mutual azo prodrugs of 5-aminosalicylic acid with Sulfamethoxazole and trimethoprim as models for colon targetingIJP. 2010;9(1):21-31. DOI: 10.33899/iphr.2010.49980.
ShaymaLuayAbdulhadi QJ. Ahlam. Synthesis of NSAID with sulfonamide conjugates as possible mutual prodrugs using amino acid spacer. IJAPBC. 2013Jan-Mar;2(1):241-8.
PoorvaJ, NivratiJ, PrateekJK.Synthesis and Characterization of Azo Conjugates of fenoprofen for treatment of inflammatory bowel disease through colon Targeting. Int J Curr Pharm Res.2015;7(4):106-10.
Mura C, Valenti D, Floris C, Sanna R, De Luca MA, Fadda AMet al.Metronidazole prodrugs: synthesis, physicochemical properties, stability, and ex vivo release studies. Eur J Med Chem.2011Sep;46(9):4142-50. doi: 10.1016/j.ejmech.2011.06.016, PMID 21726922.
Feng J, Chen Y, Li F, Cui L, Shi N, Kong Wet al.Synthesis, characterization and invitroevaluation of a novelglycolchitosan-EDTAconjugate to inhibitaminopeptidase-mediated degradation of thymopoietinoligopeptides. Molecules. 2017Jul26;22(8):1253. DOI: 10.3390/molecules22081253, PMID 28933740.
Loretz B, Bernkop-Schnürch A. In vitro evaluation of chitosan-EDTA conjugate polyplexes as a nanoparticulate gene delivery system. AAPS J.2006;8(4):E756-64. doi: 10.1208/aapsj080485, PMID 17285741.
Kumar A, Mishra A. Synthesis, characterization and release studies of ethylenediaminetetraaceticacid (EDTA)-antimicrobialdrugconjugates for colonrelease. IntJPharmInvestig. 2022;12(3):272-9. doi: 10.5530/ijpi.2022.3.48.
Bhosale AV, Agrawal GP, Mishra P. Hydrolysis kineticsstudies of mutualprodrugs of ibuprofen. Ind J Pharm Sci.2004;66(5):626-30.
Dhaneshwar SS, Gairola N, Kandpal M, Bhatt L,Vadnerkar G, Kadam SS. Synthesis, kinetic studies and pharmacological evaluation of mutual azo prodrug of 5-aminosalicylic acid with D- phenylalanine for colon-specific drug delivery in inflammatory bowel disease. Bioorg Med Chem Lett.2007Apr1;17(7):1897-902.doi: 10.1016/j.bmcl.2007.01.031, PMID 17280832.
Mostafa HF, Ibrahim MA, Mahrous GM, Sakr A. Assessment of the pharmaceutical quality of marketed enteric coated pantoprazole sodium sesquihydrate products. Saudi Pharm J.2011Apr;19(2):123-7. doi: 10.1016/j.jsps.2011.01.001. PMID 23960750.
Archie, Shrivastava AK, Pradeep.Synthesis, characterization and release studies of mutualprodrugs of norfloxacin and trimethoprim with indomethacin for colon- specific drug delivery.Int J PharmSci Invent.2014May;3(5):07-11.
Dhaneshwar SS, Gairola N, Kandpal M, Vadnerkar G, Bhatt L. Colon-specific, mutual azo prodrug of 5-aminosalicylic acid with L-tryptophan: Synthesis, kinetic studies and evaluation of its mitigating effect in trinitrobenzene sulfonic acid-induced colitis in rats. Bioorg Med Chem. 2007;15(14):4903-9. doi: 10.1016/j.bmc.2007.04.045. PMID 17499512.
Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology. 1989;96(3):795-803. doi: 10.1016/0016-5085(89)90904-9, PMID 2914642.
Onishi H, Oosegi T, Machida Y. Efficacy and toxicity of Eudragit-coated chitosan-succinyl-prednisolone conjugate microspheres using rats with 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Int J Pharm.2008Jun24;358(1-2):296-302. doi: 10.1016/j.ijpharm.2008.02.015, PMID 18394832.
Hartmann G, Bidlingmaier C, Siegmund B, Albrich S, Schulze J, Tschoep Ket al.Specific type IV phosphodiesterase inhibitor Rolipram mitigates experimental colitis in mice. JPharmacolExpTher.2000Jan;292(1):22-30. PMID 10604928.
Lamprecht A, Ulbrich N, Yamamoto H, Schäfer U, Takeuchi H, Maincent Pet al.Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. JPharmacolExpTher.2001Nov;299(2):775-81. PMID 11602694.
Zingarelli B, Squadrito F, Graziani P, Camerini R, Caputi AP. Effects of zileuton, a new 5-lipoxygenase inhibitor, in experimentally induced colitis in rats. AgentsActions. 1993Jul;39(3-4):150-6. doi: 10.1007/BF01998968, PMID 7905704.
Kalsi PS. Spectroscopy of organiccompounds.6th ed, New Delhi, New age International Pvt. Ltd; 2014. p. 65-512.
Silverstein RM, Webster FX. Spectrometric identification of organiccompounds. 6thed.John Wiley & Sons, Inc; 2004. p. 2-232.
Sharma YR.Elementary organic spectroscopy. Principles and chemicalapplications. 1sted (reprint).New Delhi:S Chand, and Company Ltd; 2018. p. 75-364.
Jung Y, Kim YM. What should be considered on design of a colon-specific prodrug?Expert Opin Drug Deliv.2010;7(2):245-58. doi: 10.1517/17425240903490401, PMID 20095945.
Kim H, Kim D, Choi D, Jeon H, Han J, Jung Y, et al. Synthesis and properties of N,N′-Bis(5-Aminosalicyl)-L-cystine as a colon-specificdeliverer of 5-aminosalicylic acid and cystine. Drug Deliv.2008;15(1):37-42. doi: 10.1080/10717540701828806, PMID 18197522.
ZouMJ, Cheng G, Okamoto H, Hao XH, AnF, Cui FDet al.Colon-specific drug delivery systems based on cyclodextrinprodrugs: in vivo evaluation of 5-aminosalicylic acid fromits cyclodextrin conjugates. World J Gastroenterol.2005;11(47):7457-60. doi: 10.3748/wjg.v11.i47.7457, PMID 16437716.
Malik T, Mannon P. Inflammatory bowel diseases: emerging therapies and promising molecular targets. Front Biosci (Schol Ed). 2012Jan1;4(3):1172-89. doi: 10.2741/s324, PMID 22202115.
te Velde AA, Verstege MI, Hommes DW. Critical appraisal of the current practice in murine TNBS-induced colitis. Inflam Bowel Dis.2006Oct;12(10):995-9. DOI: 10.1097/01.mib.0000227817.54969.5e, PMID 17012970.
Pertuit D, Moulari B, Betz T, Nadaradjane A, Neumann D, Ismaïli L, et al.5-amino salicylic acid bound nanoparticles for the therapy of inflammatory bowel disease. J Control Release.2007;123(3):211-8. DOI: 10.1016/j.jconrel.2007.08.008, PMID 17889397.
Coskun ZK, Kerem M, Gurbuz N, Omeroglu S, Pasaoglu H, Demirtas C, et al. The study of biochemical and histopathological effects of Spirulina in rats with TNBS-induced colitis. Bratisl Lek Listy. 2011;112(5):235-43. PMID 21682075.
Kim, Ho SB. Intestinal goblet cells andmucins in healthand disease: recent insights andprogress. CurrGastroenterolRep. 2010;12(5):319-30. doi: 10.1007/s11894-010-0131-2, PMID 20703838.
Published
How to Cite
Issue
Section
Copyright (c) 2022 Anoop Kumar, Ashutosh Mishra
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
